سعر كابرون 500مجم/5 مل 6 امبولات 2024

Kapron 500 mg/5 ml solution for intravenous injection (tranexamic acid 100 mg/ml), 6 ampoules, Amoun Pharmaceutical, Egypt.

• Prevention and treatment of haemorrhage due to general or local fibrinolysis in adults and children from 1 year, e.g. menorrhagia/metrorrhagia, gastrointestinal bleeding, haemorrhagic urinary disorders after prostate or urinary-tract surgery, ENT surgery (adenoidectomy, tonsillectomy, dental extraction), gynaecological/obstetric bleeding, thoracic, abdominal and cardiovascular surgery, and haemorrhage due to fibrinolytic agents.Population: Adults and children from 1 yearelectronic medicines compendium (emc), UK
• US indication: patients with haemophilia, short-term (2-8 days) to reduce or prevent haemorrhage and the need for replacement therapy during and after tooth extraction.Population: Patients with haemophiliaDailyMed (U.S. National Library of Medicine)

• Common: diarrhoea, vomiting, nausea. Uncommon: allergic dermatitis. Frequency not known: hypersensitivity incl. anaphylaxis, convulsions, visual disturbances incl. impaired colour vision, malaise with hypotension (usually after too-fast IV injection), arterial or venous thrombosis.International label, same formulation · electronic medicines compendium (emc), UK

• Hypersensitivity; acute venous or arterial thrombosis; fibrinolytic conditions following consumption coagulopathy (except predominant fibrinolytic activation with acute severe bleeding); history of convulsions; intrathecal, epidural, intraventricular injection and intracerebral application.International label, same formulation · electronic medicines compendium (emc), UK
• US label also contraindicates use in subarachnoid haemorrhage (risk of cerebral oedema and infarction) and in active intravascular clotting.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Risk of medication errors due to incorrect route: serious, including fatal, reactions (severe back/gluteal/limb pain, myoclonus, seizures, arrhythmias) after inadvertent intrathecal administration.International label, same formulation · electronic medicines compendium (emc), UK
• Convulsions (mostly with high IV doses in CABG surgery), visual disturbances (withdraw treatment), and thrombosis risk in predisposed patients; women of childbearing potential should use effective contraception.International label, same formulation · electronic medicines compendium (emc), UK
• US label: avoid concomitant factor IX complex concentrates or other prothrombotic products (thrombosis risk); dizziness may impair driving.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Prothrombotic medical products (e.g. factor IX complex, anti-inhibitor coagulant concentrates)Avoid concomitant use; may further increase the risk of thromboembolic adverse reactions.DailyMed (U.S. National Library of Medicine)

• Published data in the second and third trimesters and at delivery have not clarified a drug-associated risk of miscarriage or adverse outcomes; cases of fetal structural abnormalities after first-trimester exposure exist but risk is unclear due to confounders; tranexamic acid crosses the placenta (cord concentration similar to maternal); use only after an accurate risk-benefit evaluation.International label, same formulation · electronic medicines compendium (emc), UK
• Present in human milk; limited data on effects on the breastfed child; no final assessment can be made on use during breastfeeding.International label, same formulation · electronic medicines compendium (emc), UK

• Tranexamic acid: Competitive inhibitor of the activation of plasminogen to plasmin (non-competitive plasmin inhibitor at much higher concentrations), reducing fibrinolysis.